Avadel Pharmaceuticals PLC
AVDL21.690USD
+0.090+0.42%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
2.11BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Avadel Pharmaceuticals PLC Unternehmen
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Avadel Pharmaceuticals PLC Informationen
BörsenkürzelAVDL
Name des UnternehmensAvadel Pharmaceuticals PLC
IPO-datumFeb 21, 2088
CEODivis (Gregory J)
Anzahl der mitarbeiter188
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 21
AddresseBlock 10-1 Blanchardstown Corporate Park
StadtDUBLIN
BörseNASDAQ OMX - NASDAQ BASIC
LandIreland
Postleitzahl15
Telefon35319015201
Websitehttps://www.avadel.com/
BörsenkürzelAVDL
IPO-datumFeb 21, 2088
CEODivis (Gregory J)
Führungskräfte von Avadel Pharmaceuticals PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
--
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
--
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
--
Mr. Gregory J. (Greg) Divis, Jr.
Mr. Gregory J. (Greg) Divis, Jr.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Geoffrey M. Glass
Mr. Geoffrey M. Glass
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Courtney Turiano
Ms. Courtney Turiano
Investor Relations
Investor Relations
--
--
Dr. Naseem Amin, M.D.
Dr. Naseem Amin, M.D.
Independent Director
Independent Director
--
--
Mr. Jerad Seurer
Mr. Jerad Seurer
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
--
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
--
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
--
Mr. Gregory J. (Greg) Divis, Jr.
Mr. Gregory J. (Greg) Divis, Jr.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Mar 3
Währung: USDAktualisiert: Mon, Mar 3
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
Nach RegionUSD
Name
Umsatz
Anteil
United States
22.33M
100.00%
Ireland
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
Aktionärsstatistik
Aktualisiert: Sun, Jan 11
Aktualisiert: Sun, Jan 11
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
7.57%
BlackRock Institutional Trust Company, N.A.
6.26%
The Vanguard Group, Inc.
5.91%
Brandes Investment Partners, L.P.
5.55%
Two Seas Capital LP
5.47%
Andere
69.24%
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
7.57%
BlackRock Institutional Trust Company, N.A.
6.26%
The Vanguard Group, Inc.
5.91%
Brandes Investment Partners, L.P.
5.55%
Two Seas Capital LP
5.47%
Andere
69.24%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
34.33%
Investment Advisor
31.96%
Hedge Fund
22.84%
Research Firm
4.62%
Venture Capital
3.46%
Individual Investor
1.06%
Bank and Trust
0.84%
Pension Fund
0.48%
Insurance Company
0.03%
Andere
0.39%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
402
92.83M
119.15%
+3.65M
2025Q3
398
82.11M
112.88%
-1.35M
2025Q2
383
83.11M
109.34%
+2.70M
2025Q1
369
80.46M
107.15%
-23.08M
2024Q4
346
82.09M
100.78%
+4.35M
2024Q3
324
77.51M
94.69%
+670.00K
2024Q2
289
76.58M
80.85%
+4.27M
2024Q1
248
72.03M
68.66%
+6.05M
2023Q4
216
57.48M
70.10%
+1.83M
2023Q3
210
56.27M
69.82%
+253.21K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Janus Henderson Investors
7.43M
7.64%
-3.70M
-33.26%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.15M
6.26%
+168.04K
+2.81%
Sep 30, 2025
The Vanguard Group, Inc.
5.86M
5.98%
+285.92K
+5.13%
Dec 31, 2025
Brandes Investment Partners, L.P.
5.44M
5.55%
-1.04M
-16.07%
Sep 30, 2025
Two Seas Capital LP
5.37M
5.47%
-785.99K
-12.77%
Sep 30, 2025
Tontine Asset Management, LLC
5.31M
5.41%
+138.20K
+2.67%
Sep 30, 2025
TIG Advisors, L.L.C.
3.86M
3.93%
+384.67K
+11.07%
Dec 23, 2025
Polar Capital LLP
4.00M
4.07%
--
--
Sep 30, 2025
Highbridge Capital Management, LLC
2.05M
2.09%
+751.06K
+57.88%
Dec 12, 2025
Vivo Capital, LLC
2.68M
2.73%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Innovator IBD 50 Fund ETF
3.77%
Invesco Pharmaceuticals ETF
3.4%
iShares Neuroscience and Healthcare ETF
3.21%
ProShares Merger ETF
2.82%
State Street SPDR S&P Pharmaceuticals ETF
2.44%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.39%
AltShares Event-Driven ETF
1.21%
First Trust Small Cap Growth AlphaDEX Fund
1.02%
iShares U.S. Pharmaceuticals ETF
0.68%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.4%
Mehr Anzeigen
Innovator IBD 50 Fund ETF
Anteil3.77%
Invesco Pharmaceuticals ETF
Anteil3.4%
iShares Neuroscience and Healthcare ETF
Anteil3.21%
ProShares Merger ETF
Anteil2.82%
State Street SPDR S&P Pharmaceuticals ETF
Anteil2.44%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil2.39%
AltShares Event-Driven ETF
Anteil1.21%
First Trust Small Cap Growth AlphaDEX Fund
Anteil1.02%
iShares U.S. Pharmaceuticals ETF
Anteil0.68%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Anteil0.4%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
